0 false false false false false false false false false false true false false false false false false No description of principal activity 2024-10-01 Sage Accounts Production Advanced 2025 - FRS102_2025 xbrli:pure xbrli:shares iso4217:GBP 06701482 2024-10-01 2025-09-30 06701482 2025-09-30 06701482 2024-09-30 06701482 2023-10-01 2024-09-30 06701482 2024-09-30 06701482 2023-09-30 06701482 bus:Director1 2024-10-01 2025-09-30 06701482 bus:Director2 2024-10-01 2025-09-30 06701482 core:WithinOneYear 2025-09-30 06701482 core:WithinOneYear 2024-09-30 06701482 core:AfterOneYear 2025-09-30 06701482 core:AfterOneYear 2024-09-30 06701482 core:ShareCapital 2025-09-30 06701482 core:ShareCapital 2024-09-30 06701482 core:RetainedEarningsAccumulatedLosses 2025-09-30 06701482 core:RetainedEarningsAccumulatedLosses 2024-09-30 06701482 bus:SmallEntities 2024-10-01 2025-09-30 06701482 bus:AuditExemptWithAccountantsReport 2024-10-01 2025-09-30 06701482 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 06701482 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 06701482 bus:FullAccounts 2024-10-01 2025-09-30
COMPANY REGISTRATION NUMBER: 06701482
Pharma.Direct (UK & Europe) Limited
Filleted Unaudited Financial Statements
30 September 2025
Pharma.Direct (UK & Europe) Limited
Statement of Financial Position
30 September 2025
2025
2024
Note
£
£
£
Current assets
Debtors
4
42,173
48,712
Creditors: amounts falling due within one year
5
9,089
8,945
--------
--------
Net current assets
33,084
39,767
--------
--------
Total assets less current liabilities
33,084
39,767
Creditors: amounts falling due after more than one year
6
22,838
28,741
--------
--------
Net assets
10,246
11,026
--------
--------
Pharma.Direct (UK & Europe) Limited
Statement of Financial Position (continued)
30 September 2025
2025
2024
Note
£
£
£
Capital and reserves
Called up share capital
300
300
Profit and loss account
9,946
10,726
--------
--------
Shareholders funds
10,246
11,026
--------
--------
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 16 June 2026 , and are signed on behalf of the board by:
Mr A Davis
Mr L Moynes
Director
Director
Company registration number: 06701482
Pharma.Direct (UK & Europe) Limited
Notes to the Financial Statements
Year ended 30 September 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 40 Kimbolton Road, Bedford, Bedfordshire, MK40 2NR.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities. Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability. Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity.
4. Debtors
2025
2024
£
£
Other debtors
42,173
48,712
--------
--------
5. Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
5,903
5,759
Other creditors
3,186
3,186
-------
-------
9,089
8,945
-------
-------
6. Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
22,838
28,741
--------
--------